Pemigatinib (Pemazyre)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Pemigatinib (Pemazyre), tablets, 4.5 mg, 9 mg, and 13.5 mg, oral. Indication: For the treatment of adults with previously treated, unresectable, locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement.